- Home
- LPG vs WGS Comparison
LPG vs WGS Comparison
Compare LPG & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- WGS
- Stock Information
- Founded
- LPG 2013
- WGS 2017
- Country
- LPG United States
- WGS United States
- Employees
- LPG N/A
- WGS N/A
- Industry
- LPG Marine Transportation
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- LPG Consumer Discretionary
- WGS Technology
- Exchange
- LPG Nasdaq
- WGS Nasdaq
- Market Cap
- LPG 1.3B
- WGS 1.5B
- IPO Year
- LPG 2014
- WGS N/A
- Fundamental
- Price
- LPG $25.99
- WGS $68.43
- Analyst Decision
- LPG Buy
- WGS Strong Buy
- Analyst Count
- LPG 2
- WGS 5
- Target Price
- LPG $43.00
- WGS $67.00
- AVG Volume (30 Days)
- LPG 698.5K
- WGS 753.8K
- Earning Date
- LPG 10-31-2024
- WGS 10-29-2024
- Dividend Yield
- LPG 15.38%
- WGS N/A
- EPS Growth
- LPG N/A
- WGS N/A
- EPS
- LPG 5.82
- WGS N/A
- Revenue
- LPG $498,825,986.00
- WGS $267,228,000.00
- Revenue This Year
- LPG N/A
- WGS $43.70
- Revenue Next Year
- LPG $1.50
- WGS $16.78
- P/E Ratio
- LPG $4.47
- WGS N/A
- Revenue Growth
- LPG 1.76
- WGS 29.41
- 52 Week Low
- LPG $25.80
- WGS $1.29
- 52 Week High
- LPG $51.66
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- LPG 27.44
- WGS 51.05
- Support Level
- LPG $25.80
- WGS $71.45
- Resistance Level
- LPG $28.11
- WGS $82.18
- Average True Range (ATR)
- LPG 1.05
- WGS 7.58
- MACD
- LPG -0.05
- WGS -1.36
- Stochastic Oscillator
- LPG 3.70
- WGS 17.21
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.